PATENT CLAIM ANALYSIS

Application Number: 16017345
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["514", "364000"]

Abstract:
The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.

Claim (Index 3):
The method of  claim 1 , wherein the cancer or myeloproliferative disorder is hepatocellular carcinoma (HCC).

Metadata:
- Claim Count in Document: 38.0
- Percentile: 94.0
- Lexical Diversity: 1.24
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16017303', '14261175', '10562305', '12302953', '15954131']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.732841376573526
- 35 USC 102 Novelty (BERT): 0.6288192190098907
- Combined Prediction Score: 0.7224391608171625
- Mean Citation Score: 338.79279
- Max Citation Score: 667.3807400000002
- Similarity Product: 489.22463731648463

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test